FDA Guides Drug Makers to Faster Generic Copies
Published Date: 2/27/2026
Notice
Summary
The FDA just released new draft guides to help drug makers design tests proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by April 28, 2026, before these guides become official. These updates aim to speed up drug approvals, saving time and money for everyone.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA Posts Draft BE Study Guidances
The FDA posted new draft and revised draft product-specific guidances that give recommendations for designing bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). The notice lists many active ingredients covered (for example: apixaban, buprenorphine, semaglutide, tadalafil, acetaminophen, and others) and the FDA is accepting comments on these drafts through April 28, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in